Altretm1.1Hbgl/Altretm1.1Hbgl
Foxp3tm4(YFP/icre)Ayr/Y
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J
|
abnormal liver morphology |
J:342907
|
|
abnormal mitochondrial morphology |
J:342907
|
|
abnormal mitochondrial physiology |
J:342907
|
|
abnormal regulatory T cell physiology |
J:342907
|
|
decreased mitochondrial size |
J:342907
|
|
decreased regulatory T cell number |
J:342907
|
|
decreased T cell number |
J:342907
|
|
increased CD8-positive, alpha-beta T cell number |
J:342907
|
|
increased circulating alanine transaminase level |
J:342907
|
|
increased interleukin-17 secretion |
J:342907
|
|
increased liver tumor incidence |
J:342907
|
|
increased memory T cell number |
J:342907
|
|
increased regulatory T cell apoptosis |
J:342907
|
|
increased susceptibility to diet-induced hepatic steatosis |
J:342907
|
|
liver fibrosis |
J:342907
|
|
premature death |
J:342907
|
Aregtm2c(EUCOMM)Hmgu/Aregtm2c(EUCOMM)Hmgu
Foxp3tm4(YFP/icre)Ayr/Foxp3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6N
|
decreased blood oxygen saturation level |
J:224904
|
|
decreased body surface temperature |
J:224904
|
|
normal
immune system phenotype |
J:224904
|
|
increased susceptibility to Orthomyxoviridae infection |
J:224904
|
|
normal
mortality/aging |
J:224904
|
B2mtm1Jae/B2mtm1Jae
Foxp3sfOtcspf/Y
involves: 129/Rl * 129S2/SvPas
|
abnormal immune system organ morphology |
J:20865
|
|
abnormal interleukin level |
J:20865
|
|
abnormal lymph node morphology |
J:20865
|
|
abnormal tumor necrosis factor level |
J:20865
|
|
anemia |
J:20865
|
|
decreased body size |
J:20865
|
|
decreased hematocrit |
J:20865
|
|
dermatitis |
J:20865
|
|
enlarged lymph nodes |
J:20865
|
|
enlarged spleen |
J:20865
|
|
increased CD4-positive, alpha-beta T cell number |
J:20865
|
|
increased IgG level |
J:20865
|
|
increased IgM level |
J:20865
|
|
increased immunoglobulin level |
J:20865
|
|
increased plasma cell number |
J:20865
|
B9d2/Tgfb1tm1Flv/B9d2+
Foxp3tm4(YFP/icre)Ayr/Foxp3+
involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ
|
normal
growth/size/body region phenotype |
J:169839
|
|
normal
immune system phenotype |
J:169839
|
|
increased regulatory T cell number |
J:169839
|
B9d2/Tgfb1tm1Flv/Tgfb1tm2Flv
Foxp3tm4(YFP/icre)Ayr/Foxp3+
involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ
|
normal
growth/size/body region phenotype |
J:169839
|
|
normal
immune system phenotype |
J:169839
|
|
increased regulatory T cell number |
J:169839
|
Bcl2l11tm6.1Boui/Bcl2l11tm6.1Boui
Foxp3tm4(YFP/icre)Ayr/Foxp3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL
|
increased regulatory T cell number |
J:208318
|
Cd4tm1Litt/Cd4tm1Litt
Foxp3sfOtcspf/Y
involves: 129/Rl * 129S2/SvPas
|
abnormal CD8-positive, alpha beta T cell morphology |
J:20865
|
|
abnormal cytokine secretion |
J:20865
|
|
abnormal immune system organ morphology |
J:20865
|
|
enlarged lymph nodes |
J:20865
|
|
increased IgG level |
J:20865
|
|
increased IgM level |
J:20865
|
|
increased interleukin-4 secretion |
J:20865
|
|
increased interleukin-6 secretion |
J:20865
|
|
increased tumor necrosis factor secretion |
J:20865
|
|
premature death |
J:20865
|
Cd28tm1Ltu/Cd28tm1Ltu
Foxp3tm4(YFP/icre)Ayr/Foxp3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal eyelid morphology |
J:194503
|
|
decreased locomotor activity |
J:194503
|
|
decreased regulatory T cell number |
J:194503
|
|
decreased T cell proliferation |
J:194503
|
|
enlarged lymph nodes |
J:194503
|
|
enlarged spleen |
J:194503
|
|
focal hair loss |
J:194503
|
|
hunched posture |
J:194503
|
|
increased activated T cell number |
J:194503
|
|
increased B cell number |
J:194503
|
|
increased susceptibility to autoimmune disorder |
J:194503
|
|
increased susceptibility to experimental autoimmune encephalomyelitis |
J:194503
|
|
ruffled hair |
J:194503
|
|
skin inflammation |
J:194503
|
|
skin lesions |
J:194503
|
Cishtm1.1Cdon/Cishtm1.1Cdon
Foxp3tm4(YFP/icre)Ayr/Foxp3+
involves: 129S/Sv * 129X1/SvJ * C57BL/6
|
normal
immune system phenotype |
J:204829
|
Ctla4tm1Saka/Ctla4tm1Saka
Foxp3tm1(cre)Saka/Y
involves: BALB/c
|
abnormal immunoglobulin level |
J:140085
|
|
abnormal liver morphology |
J:140085
|
|
abnormal regulatory T cell physiology |
J:140085
|
|
abnormal splenic cell ratio |
J:140085
|
|
enlarged heart |
J:140085
|
|
increased autoantibody level |
J:140085
|
|
increased IgE level |
J:140085
|
|
increased IgG level |
J:140085
|
|
increased inflammatory response |
J:140085
|
|
increased interferon-gamma secretion |
J:140085
|
|
increased interleukin-2 secretion |
J:140085
|
|
increased interleukin-4 secretion |
J:140085
|
|
increased regulatory T cell number |
J:140085
|
|
lung inflammation |
J:140085
|
|
lymph node hyperplasia |
J:140085
|
|
myocarditis |
J:140085
|
|
premature death |
J:140085
|
|
salivary gland inflammation |
J:140085
|
|
spleen hyperplasia |
J:140085
|
|
stomach inflammation |
J:140085
|
Dicer1tm1Bdh/Dicer1tm1Bdh
Foxp3tm4(YFP/icre)Ayr/Y
involves: 129S1/Sv * 129X1/SvJ
|
blood vessel inflammation |
J:138683
|
|
enlarged lymph nodes |
J:138683
|
|
enlarged spleen |
J:138683
|
|
liver inflammation |
J:138683
|
|
lung inflammation |
J:138683
|
|
premature death |
J:138683
|
Dicer1tm1Bdh/Dicer1tm1Bdh
Foxp3tm4(YFP/icre)Ayr/Foxp3tm4(YFP/icre)Ayr
involves: 129S1/Sv * 129X1/SvJ
|
blood vessel inflammation |
J:138683
|
|
enlarged lymph nodes |
J:138683
|
|
enlarged spleen |
J:138683
|
|
liver inflammation |
J:138683
|
|
lung inflammation |
J:138683
|
|
premature death |
J:138683
|
Droshatm1Litt/Droshatm1.1Litt
Foxp3tm4(YFP/icre)Ayr/Y
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N
|
abnormal interferon-gamma secretion |
J:138683
|
|
abnormal interleukin-4 secretion |
J:138683
|
|
abnormal T cell activation |
J:138683
|
|
blood vessel inflammation |
J:138683
|
|
enlarged lymph nodes |
J:138683
|
|
enlarged spleen |
J:138683
|
|
increased CD8-positive, alpha-beta T cell number |
J:138683
|
|
increased leukocyte cell number |
J:138683
|
|
liver inflammation |
J:138683
|
|
lung inflammation |
J:138683
|
|
premature death |
J:138683
|
Droshatm1Litt/Droshatm1.1Litt
Foxp3tm4(YFP/icre)Ayr/Foxp3tm4(YFP/icre)Ayr
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N
|
abnormal interferon-gamma secretion |
J:138683
|
|
abnormal interleukin-4 secretion |
J:138683
|
|
abnormal regulatory T cell morphology |
J:138683
|
|
abnormal T cell activation |
J:138683
|
|
blood vessel inflammation |
J:138683
|
|
enlarged lymph nodes |
J:138683
|
|
enlarged spleen |
J:138683
|
|
increased CD8-positive, alpha-beta T cell number |
J:138683
|
|
increased leukocyte cell number |
J:138683
|
|
liver inflammation |
J:138683
|
|
lung inflammation |
J:138683
|
|
premature death |
J:138683
|
Foxo1tm1Flv/Foxo1tm1Flv
Foxp3tm4(YFP/icre)Ayr/Foxp3+
involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ
|
abnormal inflammatory response |
J:189962
|
|
abnormal regulatory T cell physiology |
J:189962
|
|
abnormal skin appearance |
J:189962
|
|
abnormal tail morphology |
J:189962
|
|
enlarged lymph nodes |
J:189962
|
|
enlarged spleen |
J:189962
|
|
hunched posture |
J:189962
|
|
increased CD4-positive, alpha-beta T cell number |
J:189962
|
|
increased CD8-positive, alpha-beta T cell number |
J:189962
|
|
increased interferon-gamma secretion |
J:189962
|
|
increased regulatory T cell number |
J:189962
|
|
increased T cell number |
J:189962
|
|
increased T cell proliferation |
J:189962
|
|
paralysis |
J:189962
|
|
premature death |
J:189962
|
Foxo1tm1Flv/Foxo1tm1Flv
Gt(ROSA)26Sortm1(CAG-FOXO1,GFP)Moli/Gt(ROSA)26Sor+
Foxp3tm4(YFP/icre)Ayr/Foxp3+
involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6
|
normal
immune system phenotype |
J:189962
|
|
normal
mortality/aging |
J:189962
|
Foxo1tm1Flv/Foxo1tm1Flv
Ifngtm1Ts/Ifngtm1Ts
Foxp3tm4(YFP/icre)Ayr/Foxp3+
involves: 129S1/Sv * 129S6/SvEvTac * 129S7/SvEvBrd * 129X1/SvJ
|
normal
immune system phenotype |
J:189962
|
|
increased CD4-positive, alpha-beta T cell number |
J:189962
|
|
increased CD8-positive, alpha-beta T cell number |
J:189962
|
|
normal
mortality/aging |
J:189962
|
Foxp3sfOtcspf/Y
involves: 129/Rl
|
anemia |
J:20865
|
|
decreased body weight |
J:20865
|
|
decreased hematocrit |
J:20865
|
|
enlarged lymph nodes |
J:20865
|
|
enlarged spleen |
J:20865
|
|
increased CD4-positive, alpha-beta T cell number |
J:20865
|
|
postnatal lethality, incomplete penetrance |
J:20865
|
|
premature death |
J:20865
|
|
skin lesions |
J:20865
|
Foxp3tm1.1Ayr/Foxp3tm1.1Ayr
Mir146tm1.1Bal/Mir146tm1.1Bal
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal lymphocyte physiology |
J:167922
|
|
blepharitis |
J:167922
|
|
conjunctivitis |
J:167922
|
|
decreased interferon-gamma secretion |
J:167922
|
|
dermatitis |
J:167922
|
|
increased regulatory T cell number |
J:167922
|
|
premature aging |
J:167922
|
Foxp3tm1.1Ayr/Y
Rag1tm1Mom/Rag1tm1Mom
Tg(TcraTcrb)425Cbn/0
Not Specified
|
normal
immune system phenotype |
J:97029
|
|
no abnormal phenotype detected |
J:97029
|
Foxp3tm1.1Mal/Foxp3tm1.1Mal
Lattm1.1Mal/Lattm1.1Mal
involves: 129S2/SvPas * C57BL/6
|
abnormal regulatory T cell physiology |
J:131351
|
|
decreased regulatory T cell number |
J:131351
|
|
thymus hypoplasia |
J:131351
|
Foxp3tm1Flv/Foxp3+
B9d2/Tgfb1tm1Flv/Tgfb1tm2Flv
Tg(Cd4-cre)1Cwi/?
involves: 129S6/SvEvTac * C57BL/6 * DBA/2
|
increased regulatory T cell number |
J:123547
|
Foxp3tm1Kuch/?
Il6tm1Kopf/Il6tm1Kopf
involves: 129S2/SvPas * C57BL/6
|
abnormal CD4-positive T cell differentiation |
J:123352
|
|
decreased circulating interleukin-6 level |
J:123352
|
|
decreased interleukin-17 secretion |
J:123352
|
|
decreased susceptibility to experimental autoimmune encephalomyelitis |
J:123352
|
|
increased regulatory T cell number |
J:123352
|
Foxp3tm1Tch/Y
Stat6tm1Gru/Stat6tm1Gru
C.129-Stat6tm1Gru Foxp3tm1Tch
|
abnormal cytokine secretion |
J:117165
|
|
normal
immune system phenotype |
J:117165
|
|
increased circulating interferon-gamma level |
J:117165
|
|
increased eosinophil cell number |
J:117165
|
|
lethality at weaning, complete penetrance |
J:117165
|
|
normal
respiratory system phenotype |
J:117165
|
Foxp3tm2.1(EGFP/cre)Shori/Foxp3tm2.1(EGFP/cre)Shori
Pdcd1tm1Hon/Pdcd1tm1Hon
involves: 129 * 129S2/SvPas * C57BL/6
|
premature death |
J:234397
|
Foxp3tm2.1(EGFP/cre)Shori/Y
Pdcd1tm1Hon/Pdcd1tm1Hon
involves: 129 * 129S2/SvPas * C57BL/6
|
decreased circulating lipase level |
J:234397
|
|
enlarged lymph nodes |
J:234397
|
|
enlarged spleen |
J:234397
|
|
increased effector memory T-helper cell number |
J:234397
|
|
increased susceptibility to autoimmune disorder |
J:234397
|
|
lymph node hyperplasia |
J:234397
|
|
pancreas atrophy |
J:234397
|
|
pancreas inflammation |
J:234397
|
|
premature death |
J:234397
|
|
spleen hyperplasia |
J:234397
|
Foxp3tm2Ayr/Foxp3+
Rnf128tm1Cdon/Rnf128tm1Cdon
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal regulatory T cell physiology |
J:160681
|
Foxp3tm2Ayr/?
Zap70rps/Zap70rps
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal CD4-positive, alpha beta T cell morphology |
J:211510
|
|
abnormal double-positive T cell morphology |
J:211510
|
|
abnormal regulatory T cell number |
J:211510
|
|
abnormal T cell differentiation |
J:211510
|
|
decreased CD4-positive, alpha-beta T cell number |
J:211510
|
|
decreased CD8-positive, alpha-beta T cell number |
J:211510
|
|
normal
immune system phenotype |
J:211510
|
Foxp3tm3(HBEGF/GFP)Ayr/Foxp3+
Gpr174tm1Cys/Gpr174+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J
|
decreased susceptibility to experimental autoimmune encephalomyelitis |
J:222307
|
Foxp3tm3(HBEGF/GFP)Ayr/Foxp3tm3(HBEGF/GFP)Ayr
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:117743
|
|
abnormal dendritic cell physiology |
J:117743
|
|
bradykinesia |
J:117743
|
|
cachexia |
J:117743
|
|
conjunctivitis |
J:117743
|
|
decreased T cell number |
J:117743
|
|
dermatitis |
J:117743
|
|
enlarged spleen |
J:117743
|
|
increased dendritic cell number |
J:117743
|
|
increased susceptibility to autoimmune disorder |
J:117743
|
|
increased susceptibility to induced morbidity/mortality |
J:117743
|
|
liver inflammation |
J:117743
|
|
lung inflammation |
J:117743
|
|
lymph node inflammation |
J:117743
|
|
weight loss |
J:117743
|
Foxp3tm4(YFP/icre)Ayr/Foxp3+
Nr4a2tm1.1Pcn/Nr4a2tm1.1Pcn
involves: 129S1/Sv * 129X1/SvJ
|
abnormal regulatory T cell morphology |
J:205658
|
|
abnormal regulatory T cell physiology |
J:205658
|
Foxp3tm4(YFP/icre)Ayr/Foxp3tm4(YFP/icre)Ayr
Ikzf4tm1Djr/Ikzf4tm1Djr
involves: 129S1/Sv * 129X1/SvJ
|
abnormal small intestine morphology |
J:294549
|
|
chronic inflammation |
J:294549
|
|
decreased regulatory T cell number |
J:294549
|
|
decreased small intestinal microvillus size |
J:294549
|
|
enlarged lymph nodes |
J:294549
|
|
enlarged spleen |
J:294549
|
|
glomerulonephritis |
J:294549
|
|
granulomatous inflammation |
J:294549
|
|
increased germinal center B cell number |
J:294549
|
|
increased immunoglobulin level |
J:294549
|
|
increased spleen B cell follicle number |
J:294549
|
|
increased spleen germinal center number |
J:294549
|
|
increased susceptibility to experimental autoimmune encephalomyelitis |
J:294549
|
|
increased T cell number |
J:294549
|
|
increased T follicular helper cell number |
J:294549
|
|
small intestinal inflammation |
J:294549
|
Gt(ROSA)26Sortm1(CAG-FOXO1,GFP)Moli/Gt(ROSA)26Sor+
Foxp3tm4(YFP/icre)Ayr/Foxp3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
normal
immune system phenotype |
J:189962
|
Il10tm1Roer/Il10tm1Roer
Foxp3tm4(YFP/icre)Ayr/Y
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal regulatory T cell physiology |
J:134513
|
|
abnormal type IV hypersensitivity reaction |
J:134513
|
|
colitis |
J:134513
|
|
decreased interleukin-10 secretion |
J:134513
|
|
lung inflammation |
J:134513
|
Itchtm1.1Alta/Itchtm1.1Alta
Foxp3tm4(YFP/icre)Ayr/Foxp3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal immunoglobulin level |
J:204685
|
|
abnormal interleukin secretion |
J:204685
|
|
abnormal lymph organ size |
J:204685
|
|
abnormal lymphopoiesis |
J:204685
|
|
abnormal regulatory T cell physiology |
J:204685
|
|
abnormal T-helper 2 cell differentiation |
J:204685
|
|
abnormal T-helper 2 physiology |
J:204685
|
|
decreased CD4-positive, alpha-beta T cell number |
J:204685
|
|
dermatitis |
J:204685
|
|
enlarged lymph nodes |
J:204685
|
|
enlarged spleen |
J:204685
|
|
normal
immune system phenotype |
J:204685
|
|
increased CD4-positive, alpha-beta T cell number |
J:204685
|
|
increased CD8-positive, alpha-beta T cell number |
J:204685
|
|
increased eosinophil cell number |
J:204685
|
|
increased IgA level |
J:204685
|
|
increased IgE level |
J:204685
|
|
increased IgG1 level |
J:204685
|
|
increased inflammatory response |
J:204685
|
|
increased interleukin-4 secretion |
J:204685
|
|
increased interleukin-5 secretion |
J:204685
|
|
increased interleukin-10 secretion |
J:204685
|
|
increased interleukin-13 secretion |
J:204685
|
|
increased interleukin-17 secretion |
J:204685
|
|
increased leukocyte cell number |
J:204685
|
|
increased regulatory T cell apoptosis |
J:204685
|
|
increased regulatory T cell number |
J:204685
|
|
lung inflammation |
J:204685
|
|
premature death |
J:204685
|
|
skin lesions |
J:204685
|
|
weight loss |
J:204685
|
Itchtm1.1Alta/Itchtm1.1Alta
Gt(ROSA)26Sortm1Hjf/Gt(ROSA)26Sor+
Foxp3tm4(YFP/icre)Ayr/Foxp3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
normal
immune system phenotype |
J:204685
|
|
increased inflammatory response |
J:204685
|
Myd88tm1.1Medz/Myd88tm1.1Medz
Foxp3tm4(YFP/icre)Ayr/Foxp3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
normal
immune system phenotype |
J:209373
|
Nr4a1tm1Pcn/Nr4a1tm1Pcn
Foxp3tm4(YFP/icre)Ayr/Foxp3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
normal
immune system phenotype |
J:205658
|
Nr4a2tm1.1Pcn/Nr4a2+
Foxp3tm4(YFP/icre)Ayr/Foxp3+
involves: 129S1/Sv * 129X1/SvJ
|
abnormal regulatory T cell morphology |
J:205658
|
Socs1tm1Ayos/Socs1tm1Ayos
Foxp3tm4(YFP/icre)Ayr/Foxp3+
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ
|
blepharitis |
J:167922
|
|
conjunctivitis |
J:167922
|
|
dermatitis |
J:167922
|
|
increased regulatory T cell number |
J:167922
|
Tg(Foxp3-HBEGF/EGFP)23.2Spar/0
involves: C57BL/6NCrl
|
abnormal pulmonary alveolus morphology |
J:125295
|
|
decreased regulatory T cell number |
J:125295
|
|
enlarged lymph nodes |
J:125295
|
|
enlarged spleen |
J:125295
|
|
epidermal hyperplasia |
J:125295
|
|
normal
immune system phenotype |
J:125295
|
|
increased inflammatory response |
J:125295
|
|
increased spleen red pulp amount |
J:125295
|
|
increased spleen white pulp amount |
J:125295
|
|
increased susceptibility to type IV hypersensitivity reaction |
J:125295
|
|
insulitis |
J:125295
|
|
lung inflammation |
J:125295
|
|
lymph node hyperplasia |
J:125295
|
|
skin inflammation |
J:125295
|
Excel File
Analysis Tools